Scientific publications

A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.

Project Indication

ODM-203

(targeted FGFR+VEGFR inhibitor)

Solid tumours

Congress posters

ESMO 2018

 

 

Cholangiocarcinoma Foundation Annual Conference 2017

 
ESMO 2016

 


ASCO 2016

 

 

Scientific articles

Holmström et al; Mol Can Ther 

 

19-23 October 2018

 

 

1-3 February 2017



7-11 October 2016

 


3-7 June 2016

 

 

 

9 October 2018
 

 

Phase 1/2 study of ODM-203, e selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors 

 

Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

 

ODM-203 a selective inhibitor of FGFR and VEGFR, shows strong anti-tumor activity, and induces anti-tumor immunity. Open access 

ODM-207

(BET protein inhibitor)

Cancer

  
   

Congress posters

AACR Annual Meeting 2019

 

 

EORTC 2018

 

 

AACR Annual Meeting 2018

 


2nd European Cancer Epigenetics

Conference 

 

AACR Annual Meeting 2017
 

 

29 March - 4 April 2019

 

 

13-16 November 2018

 

 

14-18 April 2018

 


11-13 May 2017

 

 

1-5 April 2017

 

ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer

Antitumor activity of ODM-207, a novel BET bromodomain inhibitor, in nonclinical models of ER+ breast cancer as single agent and a a combination treatment

Therapeutic targeting of estrogen receptor positive breast cancer with the BET bromodomain inhibitor ODM-207

 

Targeting cancer with a novel BET bromodomain inhibitor



Targeting cancer with a novel BET bromodomain inhibitor

 

Immune-mediated anti-tumor activity with a clinical stage BET bromodomain inhibitor ODM-207 in pre-clinical models

ODM-208 

(CYP11A1 inhibitor)

Prostate cancer (CRPC)

     

Congress posters

ENDO 2019

 

 

ESMO 2018

 


ASCO GU 2018

 

 

 

The 24th Annual PCF Scientific Retreat

 

 

ESMO 2017

 

 

23-26 March 2019

 

 

19-23 October 2018

 

8-10 February 2018

 

 


5-7 October 2017

 

 

8-12 September 2017

 

CYP11A1 Inhibition as a Therapeutic Approach for the Treatment of Castration Resistant Prostate Cancer

CYP11A1 inhibitor as a therapeutic approach for the treatment of castration resistant prostate cancer

 

CYP11A1 inhibitor as a threapeutic approach for the treatment of castration resistant prostate cancer

 

ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer

 

ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer
 

ODM-104

(more effective COMT inhibitor)

Parkinson's disease

Congress posters

MDS 2018

 

 

EAN 2018

 

 

 

 

 

 

AAN 2018

 

 

5-9 October 2018

 

 

16-19 June 2018

 

 

 

 

 

 

21-27 April 2018

 

 

 ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subject

 

 Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ODM-104 a Novel Catechol-O-Methyltransferase Inhibitor, after Single Escalating Doses in Healthy Subjects

 

Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ODM-104 a Novel Catechol-O-Methyltransferase Inhibitor, after Escalating Repeated Doses in Healthy Subjects

 

ODM-104 and optimized carbidopa dose show beneficial effect on levodopa PK in healthy subjects

 

ODM-109

(oral levosimendan)

ALS

Congress posters

NEALS 2019 

 

 

 

 

 

 

 

 

 

ENCALS 2019

 

ALS / MND 2018

 

 

NEALS 2018

 

 

ALS / MND 2017

 

 

2-4 October 2019

 

 

 

 

 

 

 

 

 

15-17 May 2019

 

7-9 December 2018

 

 

2-4 October 2018

 

 

8-10 December 2017

 

 

 

Biomarker analysis in oral levosimendan phase 2 clinical trial LEVALS

 

Baseline characteristics and status update of REFALS: a phase 3 study comparing oral levosimendan (ODM-109) to placebo in patients with ALS

 

The REFALS-ES opel-label extension study of oral levosimendan (ODM-109)

 

Safety and tolerability of oral levosimendan

 

Oral levosimendan in ALS: the REFALS phase 3 study design

 

 

Oral levosimendan in ALS: the REFALS phase 3 study design

 

 Scientific background for developing oral levosimendan (ODM-109) for the treatment of Amyotrophic Lateral Sclerosis

 

Oral levosimendan (ODM-109): Key placebo-controlled results from the phase 2 study in ALS patients with SVC between 60-90% predicted at screening